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Abstract
 
Experimental autoimmune encephalomyelitis (EAE) serves as a prototypic model for T cell–
mediated autoimmunity. V
 
 
 
14 natural killer T (NKT) cells are a subset of T lymphocytes that
recognize glycolipid antigens presented by the nonpolymorphic major histocompatibility com-
plex (MHC) class I–like protein CD1d. Here, we show that activation of V
 
 
 
14 NKT cells by
the glycosphingolipid 
 
 
 
-galactosylceramide (
 
 
 
-GalCer) protects susceptible mice against EAE.
 
 
 
-GalCer, which binds CD1d but is not recognized by NKT cells, failed to protect mice
against EAE. Furthermore, 
 
 
 
-GalCer was unable to protect 
 
CD1d
 
 knockout (KO) mice
against EAE, indicating the requirement for an intact CD1d antigen presentation pathway.
Protection of disease conferred by 
 
 
 
-GalCer correlated with its ability to suppress myelin an-
tigen-specific Th1 responses and/or to promote myelin antigen-specific Th2 cell responses.
 
 
 
-GalCer was unable to protect 
 
IL-4
 
 KO and 
 
IL-10
 
 KO mice against EAE, indicating a criti-
cal role for both of these cytokines. Because recognition of 
 
 
 
-GalCer by NKT cells is phylo-
genetically conserved, our findings have identified NKT cells as novel target cells for treatment
of inflammatory diseases of the central nervous system.
Key words: CD1d • NKT cells • experimental autoimmune encephalomyelitis • 
autoimmunity • immunotherapy
 
Introduction
 
Multiple sclerosis (MS)
 
*
 
 is a chronic inflammatory disease
of the central nervous system (CNS). Although its precise
etiology remains unknown, MS patients typically have cir-
culating T cells directed against the major components of
the myelin sheath, suggesting that autoimmunity plays a
role in the pathogenesis of MS. Experimental autoimmune
encephalomyelitis (EAE) is an autoimmune inflammatory
disease that shows many similarities to MS (1). EAE can be
induced in susceptible mouse strains by injection of CNS
proteins or peptides in adjuvant or by the passive transfer of
T cells reactive against such CNS antigens. In both MS and
EAE high levels of Th1 cytokines are detected in the CNS
at the peak of disease. Most studies have suggested that my-
elin-specific Th1 cells secreting IFN-
 
 
 
, TNF-
 
 
 
, and IL-2
mediate EAE (2, 3), whereas myelin-specific Th2 cells pro-
ducing IL-4 and IL-10 play a regulatory role and are associ-
ated with recovery from disease (4–6). Studies with animal
models have demonstrated that modulation of immune re-
sponses from a Th1-dominant to a Th2-dominant response
can effectively protect mice against EAE (for reviews, see
references 7 and 8).
Natural killer T (NKT) cells are a unique subset of T
lymphocytes that share receptor structures and characteris-
tics with NK cells (for reviews, see references 9–12). A key
feature of NKT cells is the expression of a heavily biased
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TCR, containing V
 
 
 
14-J
 
 
 
281 and V
 
 
 
8.2, -7, or -2 chains
in mice. A similar population of cells, expressing homolo-
gous TCR chains (V
 
 
 
24-J
 
 
 
Q and V
 
 
 
11), has been identi-
fied in humans (13). NKT cells are abundant in the thy-
mus, liver, and bone marrow, and are also found in
peripheral lymphoid organs. One striking property of NKT
cells is their capacity to rapidly secrete large amounts of cy-
tokines, including IL-4 and IFN-
 
 
 
, in response to TCR li-
gation. Unlike conventional T cells that recognize peptides
bound by polymorphic molecules encoded by the MHC,
NKT cells are specific for lipid antigens bound by the non-
polymorphic MHC class I–like protein CD1d. Studies with
 
CD1d
 
-deficient animals have demonstrated that CD1d ex-
pression is required for the development of NKT cells that
express the invariant V
 
 
 
14 TCR (14–16).
Although their precise function remains to be elucidated,
NKT cells have been implicated in a variety of immune re-
sponses. For example, NKT cells promote protective im-
munity against the pathogens 
 
Borrelia burgdorferi
 
 (17), 
 
Leish-
mania major
 
 (18), and encephalomyocarditis virus (19) in
mice. NKT cells can also play a role in enhancing or sup-
pressing tumor immunity (20–22). A significant amount of
evidence indicates that NKT cells play a critical role in the
regulation of autoimmune responses. Defects in NKT cell
numbers and/or function were noted in a variety of mouse
strains that are genetically predisposed for development of
autoimmune diseases (23–28). Likewise, abnormalities in
the numbers and function of NKT cells have been ob-
served in patients with autoimmune diseases (29–34). NKT
cells were also shown to contribute to the induction of tol-
erance against foreign antigens, including tolerance induced
by injection of antigens into the anterior chamber of the
eye (35, 36) and tolerance induced against tissue grafts (37,
38). Collectively, these studies have indicated that NKT
cells play a critical role in the initiation and regulation of
adaptive immunity.
While several glycolipid and phospholipid antigens that
can activate NKT cells have been identified (39, 40), the
natural ligand recognized by these cells remains to be deter-
mined. One NKT cell ligand that has received significant
attention is the glycosphingolipid 
 
 
 
-galactosylceramide (
 
 
 
-
GalCer). 
 
 
 
-GalCer was originally isolated from a marine
sponge as an agent with profound antimetastatic activities
in mice (41). It is now clear that this natural product and its
synthetic homologue (KRN7000) are recognized by all
CD1d-restricted NKT cells that express the invariant V
 
 
 
14
TCR (39, 42–45). A number of studies have shown that
 
 
 
-GalCer has profound activities on innate and adaptive
immune responses. Administration of 
 
 
 
-GalCer to mice
leads to the rapid production of a variety of cytokines, in-
cluding characteristic Th1 and Th2 cytokines (46–49). Stim-
ulation of V
 
 
 
14 NKT cells in this manner also leads to the
rapid activation of NK cells, dendritic cells, B cells, and con-
ventional T cells (46–52). In vivo activation of V
 
 
 
14 NKT
cells with 
 
 
 
-GalCer and CD1d polarizes adaptive immune
responses for production of Th2 cytokines (48, 49). Hence,
 
 
 
-GalCer may be used to shift the balance from a Th1-dom-
inant toward a Th2-dominant immune response.
 
Here, we have tested whether activation of NKT cells
can modulate immune responses against CNS antigens and
protect mice against EAE. Our results demonstrate that
 
 
 
-GalCer protects wild-type but not 
 
CD1d
 
 knockout
(KO) mice against EAE. Prevention of disease correlated
with the ability of 
 
 
 
-GalCer to promote the generation of
CNS antigen-specific Th2 cells. Studies with 
 
IL-4
 
 
 
/
 
 
 
 and
 
IL-10
 
 
 
/
 
 
 
 mice further demonstrated that both IL-4 and
IL-10 are important for 
 
 
 
-GalCer-mediated protection
against EAE. Taken together, our findings have identified
invariant NKT cells as novel target cells for therapeutic in-
tervention in inflammatory diseases of the CNS.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 (B6), B6.
 
IL-4
 
 
 
/
 
 
 
, B6.
 
IL-10
 
 
 
/
 
 
 
, PL/J,
and SJL/J (SJL) mice were purchased from The Jackson Labo-
ratory. 
 
CD1d
 
 
 
/
 
 
 
 mice have been described (14), and were back-
crossed 10 times onto the B6 background. At each backcross,
heterozygous mice were identified by tail biopsy and Southern
blot analysis, as described (14). All mice were bred and main-
tained in the animal facility at Vanderbilt University School of
Medicine (Nashville, TN).
 
Reagents.
 
Myelin oligodendrocyte glycoprotein (MOG) pep-
tide 35–55 (MOG
 
35–55
 
), MEVGWYRSPFSRVVHLYRNGK,
was synthesized by the HHMI biopolymer facility at Duke Uni-
versity (Durham, NC). Myelin basic protein (MBP) was purified
from guinea pig spinal cord (Harlan Sprague Dawley Inc.), as de-
scribed (53). 
 
 
 
-GalCer is a glycosphingolipid that was originally
isolated as a natural product from the marine sponge 
 
Agelas mauri-
tianus
 
 (41). In this work a synthetic form of 
 
 
 
-GalCer, KRN7000
(54), was used. KRN7000 and synthetic 
 
 
 
-GalCer were obtained
from Kirin Brewery Co., Ltd.
 
Detection of NKT Cells by Flow Cytometry.
 
The liver was per-
fused with PBS via the portal vein until blanched and distended,
and pressed through a 70-
 
 
 
m cell strainer (Becton Dickinson).
Hepatocytes were pelleted by centrifugation at 300 
 
g
 
 for 3 min.
The remaining liver cells in the supernatant were pelleted at
1,200 
 
g
 
 for 5 min and then resuspended in a 40% isotonic Percoll
solution (Amersham Pharmacia Biotech). This suspension was
underlaid with a 60% isotonic Percoll solution. After centrifuga-
tion for 20 min at 1,500 
 
g
 
, mononuclear cells were isolated at the
40/60% interface. The cells were subsequently washed once
with RPMI 1640 (Life Technologies) supplemented with 5%
FCS (HyClone Laboratories Inc.). Liver cells were stained using
anti–TCR-
 
 
 
 (H57–597; BD PharMingen) and CD1d/
 
 
 
-Gal-
Cer tetramers. CD1d/
 
 
 
-GalCer tetramers were generated essen-
tially as reported (55), with minor modifications (unpublished
data). Cell suspensions (10
 
6
 
 cells) were stained using combina-
tions of FITC-labeled anti–TCR-
 
 
 
 antibodies and APC-labeled
CD1d/
 
 
 
-GalCer tetramers and analyzed by flow cytometry us-
ing a FACSCalibur™ instrument and CELLQuest™ software
(Becton Dickinson).
 
In Vitro Stimulation of Splenocytes with 
 
 
 
-GalCer.
 
Splenocytes
(2 
 
 
 
 10
 
5
 
/ well) were incubated with titrated doses of 
 
 
 
-GalCer
in RPMI 1640 supplemented with 10% FCS, 50 
 
 
 
M 2-mercap-
toethanol, 2 mM glutamine, antibiotics, and 10 mM HEPES,
for 72 h. For proliferation assays, 1 
 
 
 
Ci of [
 
3
 
H]thymidine
(PerkinElmer) was then added to the wells, and after an addi-
tional 16 h of culture, cells were collected with a cell harvester
(Tomtec) and uptake of radioactivity was measured with a beta-
plate reader (Wallac). For measurement of cytokine levels, cul- 
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ture supernatants were collected and cytokine levels were deter-
mined by ELISA.
 
Induction of EAE in Mice.
 
Active EAE in mice of the B6
background was induced by immunization of 8- to 10-wk-old fe-
male animals subcutaneously with 200 
 
 
 
g of MOG
 
35–55
 
 emulsi-
fied in complete Freund’s adjuvant (Becton Dickinson) on days 0
and 7. Mice also received 500 ng of pertussis toxin (Life Technol-
ogies) intraperitoneally on days 0 and 2. For induction of EAE in
PL/J and SJL mice, 8- to 12-wk-old female animals were immu-
nized subcutaneously with 300 
 
 
 
g of MBP emulsified in CFA on
day 0. Mice receive 500 ng of pertussis toxin intraperitoneally on
days 0 and 2.
 
Clinical Evaluation of EAE.
 
Clinical symptoms were moni-
tored daily after the first immunization. The clinical score was
graded as follows: 0, no disease; 1, tail limpness; 2, hind limb
weakness; 3, hind limb paralysis; 4, fore limb weakness; 5, quadri-
plegia; 6, death. Cumulative disease scores were calculated by
adding daily disease scores from the day after immunization until
the end of the experiment.
 
Treatment of Mice with 
 
 
 
-GalCer or 
 
 
 
-GalCer.
 
Unless other-
wise noted, three injections of 
 
 
 
-GalCer (6 
 
 
 
g/mouse/injec-
tion), 
 
 
 
-GalCer (6 
 
 
 
g/mouse/injection), or vehicle (0.025%
polysorbate-20 in PBS) were performed on days 0, 4, and 7 after
immunization with CNS antigens. When performed at the same
time as antigen immunization, 
 
 
 
-GalCer, 
 
 
 
-GalCer, or vehicle
were mixed together with antigen and CFA and administered by
subcutaneous injection. For other time points, 
 
 
 
-GalCer, 
 
 
 
-Gal-
Cer, or vehicle were injected by the intraperitoneal route.
 
Measurement of Autoantigen-specific T Cell and Antibody Re-
sponses.
 
11 d after EAE induction, cells (5   105) from the
inguinal and axillary lymph nodes of immunized mice were
cultured in RPMI 1640 supplemented with 10% FCS, and
stimulated with titrated doses of MOG35–55 or MBP for 60 h. Su-
pernatants were collected and cytokine levels were measured by
ELISA. Total and antigen-specific antibody isotype levels in the
serum of immunized mice were measured by ELISA.
ELISA. A standard sandwich ELISA was used to measure
mouse IFN- , IL-4, IL-10, and antibody isotype levels. IFN- ,
IL-4, IL-10, IL-13, and total IgE were measured using purified
and biotinylated antibody pairs and standards from BD PharMin-
gen. For detection, streptavidin-horse radish peroxidase (HRP)
conjugate (Zymed Laboratories) was used in conjunction with
the substrate 3,3 ,5,5 -tetramethylbenzidine (Dako). Antigen-
specific IgE levels were measured similarly, but plates were coated
with 10  g/ml of MOG35–55 peptide instead of capture anti-IgE
antibody. For measurement of antigen-specific IgM, IgG1 and
IgG2a antibodies, immunoplates (Maxisorp; Nunc) were coated
with 10  g/ml of MOG35–55 peptide in 0.1 M Na2HPO4. After
blocking with 1% BSA in PBS, serial dilutions of antiserum were
added. Detection was performed with anti–IgM-HRP, anti–
IgG1-HRP, and anti–IgG2a-HRP antibodies (all from Southern
Biotechnology Associates, Inc.), in conjunction with the substrate
o-phenylene-diamine (Sigma-Aldrich). Concentrations were cal-
culated on the basis of standard curves of antibody isotypes (all
from Southern Biotechnology Associates, Inc.) run in parallel
ELISA assays.
Statistical Analysis. Statistical analyses were performed using
Student’s t test. P values smaller than 0.05 were considered statis-
tically significant.
Results
NKT Cell Numbers and Function in EAE-susceptible
Mice. Prior studies have shown that EAE-susceptible SJL
mice have numerical and functional defects in NK1.1  T
cells (26). Because recent studies have demonstrated that
NK1.1 is not a reliable marker for identification of V 14
NKT cells (28), we first reevaluated the relative frequency
of this cell population in different EAE-susceptible strains.
For this purpose we used tetrameric CD1d molecules
loaded with  -GalCer, which specifically react with V 14
NKT cells (55, 56). We found that B6 and PL/J mice have
similar numbers of tetramer-positive cells in their liver (Fig.
1 A) and spleen (data not shown), whereas SJL mice have
substantially lower numbers of tetramer-positive cells in
these organs (Fig. 1 A, and data not shown). Nevertheless,
numbers of tetramer-positive cells in SJL mice were signifi-
cantly higher than in CD1d-deficient mice (Fig. 1 A, and
data not shown), which have profound defects in V 14
NKT cell development (14–16, 55, 56).
To evaluate NKT cell function in EAE-susceptible
strains, we measured the proliferative and cytokine re-
Figure 1. Analysis of V 14 NKT cells in EAE-suscepti-
ble mice. (A) Numbers of CD1d/ -GalCer tetramer-posi-
tive cells in EAE-susceptible mice. Liver mononuclear cells
from the indicated mice were stained with APC-labeled
CD1d/ -GalCer tetramers and FITC-labeled anti-TCR- 
antibodies and analyzed by flow cytometry. Numbers indi-
cate the percentage of TCR-   tetramer  cells. Represen-
tative data are shown from three separate experiments. (B)
In vitro responses of spleen cells from EAE-susceptible
mice to  -GalCer. Splenocytes (2   105) from the indi-
cated mice were cultured with 50 ng/ml of  -GalCer. 3 d
later proliferation was measured by [3H]thymidine incor-
poration and cytokine production in the culture superna-
tant was measured by ELISA. Data represent the mean  
SE of three mice per group. Representative data are shown
from three separate experiments.1804 Ligand-activated NKT Cells Protect Mice against EAE
sponses of splenocytes to in vitro stimulation with  -Gal-
Cer. Our results show that these responses from B6 and
PL/J splenocytes were very similar, whereas responses
were undetectable in CD1d KO mice (Fig. 1 B). In SJL
mice, proliferation and IFN-  production in response to
 -GalCer stimulation were comparable to B6 and PL/J
mice, whereas IL-4 production was profoundly reduced
(Fig. 1 B).
Collectively, these results are in agreement with prior
studies (26), indicating that NKT cells in SJL mice are re-
duced in number and that these cells have functional de-
fects as well.
 -GalCer Protects Mice Against EAE. Next, we tested
the ability of  -GalCer to modulate EAE. For these stud-
ies, we used three different murine models for EAE: (a) dis-
ease induced in B6 (H2b) mice by immunization with the
MOG35–55 peptide, (b) PL/J (H2u) mice immunized with
MBP, and (c) SJL (H2s) mice immunized with MBP. Rep-
resentative data from these studies are shown in Fig. 2 and
pooled data for a number of separate experiments are sum-
marized in Table I. Results show that  -GalCer effectively
prevents EAE in B6 and PL/J mice, but is less effective in
SJL mice. In B6 mice, the frequency of disease was 95% in
vehicle-treated animals and 28% in  -GalCer–treated ani-
mals. The mean onset of disease was 18.0   0.7 d in vehi-
cle-treated B6 mice and 30.5   2.4 d in  -GalCer–treated
B6 mice (P   0.005). Both the mean maximum clinical
score (P   0.005) and the mean cumulative clinical score
(P   0.005) of EAE disease were profoundly reduced in
 -GalCer–treated B6 mice (Fig. 2 A, and Table I). Similar
results were obtained in PL/J mice, with substantially re-
duced disease frequency, significant delay in the onset of
EAE (P   0.005), and significant reduction in the mean
maximum (P   0.05) and mean cumulative (P   0.05)
clinical scores in  -GalCer–treated mice, compared with
vehicle-treated mice (Fig. 2 B, and Table I). Although
 -GalCer treatment significantly delayed disease onset
(P   0.05) in SJL mice, it did not significantly modulate
disease frequency and clinical score parameters, and actually
enhanced mortality (Table I).
Disease Protection Mediated by  -GalCer Requires a Func-
tional CD1d Antigen Presentation Pathway. To provide ev-
idence that the activities of  -GalCer on EAE are mediated
by stimulation of CD1d-dependent V 14 NKT cells we
tested the ability of  -GalCer, which binds with CD1d but
does not activate NKT cells (39), to modulate EAE in-
duced in B6 mice by the MOG35–55 peptide. Our results
show that  -GalCer not only fails to protect mice against
EAE, but actually enhances disease (Fig. 3 A, and Table I).
As compared with vehicle-injected mice,  -GalCer–
treated animals had quicker onset of disease (P   0.005)
and increased mean maximum and cumulative clinical
scores, although differences for the latter disease parameters
did not reach statistical significance. Mortality in  -Gal-
Cer–treated animals, compared with vehicle-treated mice,
was enhanced (Table I).
To further investigate the role of the CD1d antigen pre-
sentation pathway for the activities of  -GalCer on EAE,
we examined its ability to modulate disease in CD1d-defi-
cient mice that were backcrossed 10 times to the B6 strain.
While none of the disease parameters were significantly dif-
ferent among untreated B6.CD1d /  and B6.CD1d / 
mice (Fig. 3 B, and Table I),  -GalCer effectively pro-
tected B6.CD1d /  but not B6.CD1d /  mice against
EAE (Fig. 3 C, and Table I).
These results provide strong evidence that  -GalCer
protects mice against EAE by the CD1d-dependent activa-
tion of V 14 NKT cells.
 -GalCer Promotes CNS Antigen-specific Th2 Responses in
EAE-induced Mice. To investigate the immunological
mechanisms for disease protection mediated by  -GalCer
we measured Th cell responses directed against the immu-
nizing CNS antigens. B6 and PL/J mice were immunized
with myelin antigens and treated with vehicle or  -GalCer.
11 d after induction of EAE, we measured T cell–mediated
cytokine responses against MOG35–55 peptides and MBP in
B6 and PL/J mice, respectively. In B6 mice immunized
with MOG35–55,  -GalCer induced a sharp reduction in
IFN-  production and a significant increase in IL-10 pro-
duction by lymph node cells in response to in vitro restim-
ulation with MOG35–55 peptide, but did not significantly
influence IL-4 production by these cells (Fig. 4 A). In
MBP-immunized PL/J mice,  -GalCer treatment reduced
IFN- , enhanced IL-4 and IL-10 (Fig. 4 B), and did not
significantly influence IL-13 production (data not shown)
Figure 2.  -GalCer protects susceptible mice against EAE. EAE was
induced in B6 mice (A) by immunization with MOG35–55 peptide, and in
PL/J (B) and SJL mice (C) by immunization with MBP, as described in
Materials and Methods. Mice were treated with  -GalCer (6  g/injec-
tion) or vehicle (0.025% polysorbate-20 in PBS) on days 0, 4, and 7 after
immunization. Representative data from several independent experiments
are shown.1805 Singh et al.
by lymph node cells in response to in vitro restimulation
with MBP. Hence, we conclude that  -GalCer induces a
shift from a Th1-dominant toward a Th2-dominant myelin
antigen-specific response.
To evaluate effects of  -GalCer on humoral immune
responses in mice immunized with CNS antigens, we
measured total serum and MOG35–55–specific Ig isotype
levels 11 d after immunization and  -GalCer treatment.
We observed a significant increase in total IgE levels in
 -GalCer–treated B6 mice immunized with MOG35–55
(Fig. 5 A), but no significant  -GalCer–induced alter-
ations in serum IgE levels in PL/J mice immunized with
MBP (Fig. 5 B).  -GalCer did not significantly alter total
serum IgM, IgG1 and IgG2a levels in B6 and PL/J mice
(data not shown). Likewise, no significant differences
were observed for MOG35–55–specific IgG1 and IgG2a
levels among  -GalCer– and vehicle-treated mice, and
MOG35–55–specific IgE levels were undetectable in all
mice (data not shown).
 -GalCer Fails to Protect IL-4 KO and IL-10 KO Mice
Against EAE. To evaluate the role of the Th2 cytokines
IL-4 and IL-10 for the effects of  -GalCer on EAE, we
tested the ability of this compound to modulate disease in
IL-4 /  and IL-10 /  mice crossed onto a B6 background.
Results show that  -GalCer is unable to protect either of
these cytokine-deficient strains against EAE (Fig. 6, and
Table I). In B6.IL-4 /  mice,  -GalCer actually caused
more severe disease, with enhanced mean maximum (P  
0.05) and mean cumulative (P   0.005) clinical scores and
enhanced mortality. While  -GalCer was unable to protect
these animals against EAE, it significantly suppressed IFN- 
production by MOG35–55–specific T cells in both IL-4 KO
and IL-10 KO mice (Fig. 7), and enhanced IL-4 produc-
tion by MOG35–55–specific T cells in IL-10 KO mice (Fig.
Table I. Modulation of EAE by  -GalCer in Wild-Type and Knockout Mice
Mouse strain Treatment
Number
of mice
Onset of
disease
(d)
Disease
frequency
(%)
Mortality
(%)
Mean
maximum
score
Mean
cumulative
score
B6 Vehicle 21 18.0   0.7 95 24 4.0   0.3 117.0   17.3
 -GalCer 25 30.5   2.4a 28 8 1.3   0.3a 35.8   14.3a
PL/J Vehicle 11 15.6   1.5 80 36 3.3   0.8 144.0   50.8
 -GalCer 10 26.9   1.3a 37 0 0.97   0.7b 18.3   8.3b
SJL Vehicle 9 15.8   1.5 67 11 3.3   0.7 78.9   33.0
 -GalCer 8 23.8   1.5b 63 38 3.4   1.1c 56.7   27.6c
B6 Vehicle 5 20.4   2.0 100 20 2.5   0.7 108.0   24.1
 -GalCer 7 28.0   3.1b 40 0 1.2   1.0b 10.0   7.1a
 -GalCer 5 12.4   0.7a 100 60 5.0   0.8c 187.6   53.5c
B6.CD1d /  None 8 12.9   1.7 88 13 3.4   0.6 71.4   28.8
B6.CD1d /  None 9 11.7   0.9c 100 22 3.6   0.5c 87.3   25.9c
B6.CD1d /   -GalCer 16 18.3   2.1 25 0 0.4   0.2 5.5   4.2
B6.CD1d /   -GalCer 19 13.1   1.2a 90 5 2.2   0.3a 31.3   7.6a
B6.IL-4 /  Vehicle 11 15.9   1.2 100 64 5.0   0.4 150.2   28.2
 -GalCer 11 13.5   1.1c 100 100 6.0   0.0b 282.5   9.0a
B6.IL-10 /  Vehicle 11 14.6   1.0 100 64 5.1   0.4 188.8   37.3
 -GalCer 11 15.5   0.8c 100 55 4.2   0.6c 155.7   32.1c
EAE was induced and mice were treated with vehicle,  -GalCer or  -GalCer as described in Materials and Methods. Data shown summarize the
results of several independent experiments. Data represent the mean values   SE.
aP   0.005 when compared with vehicle-treated or B6.CD1d /  animals.
bP   0.05 when compared with vehicle-treated or B6.CD1d /  animals.
cDifferences with vehicle-treated or B6.CD1d /  animals are not statistically significant.1806 Ligand-activated NKT Cells Protect Mice against EAE
7 B). These findings indicate a critical role for both IL-4
and IL-10 in the ability of  -GalCer to protect mice
against EAE.
Discussion
EAE serves as a prototypic model for T cell–mediated
autoimmunity. At the peak of disease, high levels of Th1
cytokines are detected in the CNS (2, 3). A number of
studies have shown that treatment with Th2-promoting
cytokines or with monoclonal antibodies directed against
Th1-promoting cytokines can effectively protect mice
against EAE (for reviews, see references 7 and 8). Here, we
have shown that specific activation of V 14 NKT cells
with its ligand  -GalCer provides an alternative way to
shift the balance from a pathogenic Th1 toward a protec-
tive Th2 response. Disease protection required CD1d ex-
pression and was associated with suppressed CNS antigen-
specific Th1 responses. We also identified a critical role for
the Th2 cytokines IL-4 and IL-10 in the ability of  -Gal-
Cer to protect mice against EAE. These findings not only
support the proposed role of NKT cells in the regulation
of self-tolerance but also highlight the potential use of
 -GalCer for therapeutic intervention in a variety of Th1-
mediated diseases.
A number of different cell types play a regulatory role in
the pathogenesis of EAE. These include Th2 cells (4–6)
and other regulatory CD4  T cells (57, 58), CD8  T cells
(59–61), B cells (62), and NK cells (63). In addition, a reg-
ulatory role for NKT cells in the pathogenesis and recovery
from EAE was suggested by the finding that SJL mice have
reduced numbers of NK1.1  T cells and defects in the in
vivo cytokine response to anti-CD3 stimulation (26). Our
CD1d/ -GalCer tetramer staining (Fig. 1 A) and in vitro
 -GalCer stimulation (Fig. 1 B) experiments are in agree-
ment with this conclusion. Based on these findings, com-
plete elimination of CD1d-restricted NKT cells in mice
would be predicted to exacerbate EAE disease. However,
we found that all disease parameters in MOG35–55–immu-
nized B6.CD1d /  and B6.CD1d /  mice were indistin-
guishable (Fig. 3 B, and Table I). Because the animals used
in these experiments had been backcrossed a total of 10
times onto the B6 strain it is unlikely that this result was
due to resistance genes that were carried over from the 129
background originally used to generate the KO mice (14).
Consistent with this finding, we have recently found that
disease in V 14 transgenic B6 mice is indistinguishable
from control animals (unpublished data). Nevertheless, it
remains possible that NKT cells play a role in the regula-
tion of EAE induced by other CNS antigens and/or in
other mouse strains.
 -GalCer profoundly suppressed all disease parameters
in B6 mice immunized with MOG35–55 and PL/J mice im-
munized with MBP (Fig. 2, A and B, and Table I). In SJL
Figure 3. The capacity of  -GalCer to protect mice against EAE is
mediated by activation of CD1d-restricted NKT cells. (A)  -GalCer,
which binds with CD1d but does not activate NKT cells, fails to protect
mice against EAE. B6 mice were immunized with MOG35–55 peptide and
treated with  -GalCer (6  g/injection),  -GalCer (6  g/injection), or
vehicle. (B) CD1d deficiency does not exacerbate EAE in B6 mice.
B6.CD1d /  and B6.CD1d /  mice from the 10th backcross to B6 were
immunized with MOG35–55 peptide. (C) Protection against EAE requires
CD1d expression in mice. EAE was induced in B6.CD1d /  and
B6.CD1d /  mice by immunization with MOG35–55. Mice were treated
with  -GalCer (4  g/injection) on days 0 and 7.
Figure 4.  -GalCer promotes antigen-specific Th2 re-
sponses in mice immunized with CNS antigens. B6 mice
(A) were immunized with MOG35–55 and PL/J mice (B)
were immunized with MBP to induce EAE. Mice were
treated with  -GalCer or vehicle as described in the leg-
end to Fig. 2. At day 11 after immunization cells from in-
guinal and axillary lymph nodes were cultured with the in-
dicated concentrations (in  g/ml) of MOG35–55 peptide
(A) or MBP (B). After 60 h of culture, supernatants were
collected and cytokine levels were measured by ELISA.
Data shown represent the mean values   SE of 6 mice in
each experimental group. Representative data are shown
from three separate experiments.1807 Singh et al.
mice immunized with MBP  -GalCer significantly de-
layed the onset of disease, but did not significantly alter
other disease parameters (Fig. 2 C, and Table I). The re-
duced efficacy of  -GalCer for treatment of EAE disease in
SJL mice is consistent with the reduced numbers of V 14
NKT cells in these animals (Fig. 1 A) and with the func-
tional defects of splenocytes to in vitro stimulation with
 -GalCer, in particular the profound reduction in IL-4 re-
sponses (Fig. 1 B).
The requirement for CD1d molecules and V 14 NKT
cells in the effects of  -GalCer on EAE was demonstrated
by the failure of  -GalCer to protect mice against disease
(Fig. 3 A), and the inability of  -GalCer to prevent disease
in CD1d-deficient mice (Fig. 3 C). Although  -GalCer
can bind with CD1d molecules, it does not activate V 14
NKT cell hybridomas nor does it stimulate in vitro cyto-
kine production by splenocytes (39) (unpublished data). It is
therefore surprising that  -GalCer actually enhances disease
in B6 mice immunized with MOG35–55 (Fig. 3 A, and Ta-
ble I). One potential explanation for this unexpected find-
ing is that  -GalCer competes with an endogenous ligand
for binding with CD1d and thus prevents or perhaps antag-
onizes NKT cell recognition of endogenous antigens. The
precise mechanism by which  -GalCer exacerbates disease
requires further investigation.
Activation of V 14 NKT cells leads to the rapid produc-
tion of a variety of cytokines (46, 48, 49, 51), including IL-4
and IL-10, which promote Th2 differentiation, and IFN- ,
which promotes Th1 differentiation. It was also shown
that administration of  -GalCer to mice polarizes V 14
NKT cells for loss of IFN-  but maintenance of IL-4 pro-
duction (48, 49). In turn, injection of  -GalCer into mice
polarizes Th cell responses for Th2 differentiation (48, 49).
In this study, we found that  -GalCer similarly suppresses
Th1 and/or enhances Th2 differentiation of CNS antigen-
specific T cells (Fig. 4). Because Th2 cytokines can suppress
EAE (for reviews, see references 7 and 8), it is tempting to
speculate that the activities of  -GalCer on EAE are due to
its effects on the differentiation of autoantigen-specific Th
cells. The cytokines produced by  -GalCer–activated
NKT cells (i.e., IL-4 and IL-10) may directly influence the
differentiation of autoantigen-specific Th cells. Alterna-
tively,  -GalCer–activated NKT cells may influence Th
cell differentiation through their activities on antigen-pre-
senting cells (47, 48, 51). Our finding that  -GalCer fails to
protect IL-4 KO and IL-10 KO mice against EAE (Fig. 6,
and Table I) is in agreement with a critical role of Th2 cy-
tokines. Th2 cytokine production by both NKT cells and
CNS antigen-specific Th cells may be important for the
protective effects of  -GalCer on EAE disease. This issue
will be addressed in future studies.
Collectively, our studies suggest the following sequence
of events to account for the ability of  -GalCer to protect
Figure 5. IgE antibody production in the serum of mice immunized
with CNS antigens and treated with  -GalCer. EAE was induced in B6
mice (A) by immunization with MOG35–55 peptide and in PL/J (B) mice
by immunization with MBP. Mice were treated with  -GalCer or vehi-
cle as described in the legend to Fig. 2. Mice were bled on day 11 after
immunization and total IgE levels in the serum were measured by
ELISA. Data shown represent the mean values   SE of four (A) or six
(B) mice in each experimental group. Representative data are shown
from two separate experiments.
Figure 6.  -GalCer fails to protect IL-4 KO and IL-10 KO mice
against EAE. B6.IL-4 /  (A) and B6.IL-10 /  (B) mice were immunized
with MOG35–55 peptide to induce EAE and treated with  -GalCer or ve-
hicle as described in the legend to Fig. 2. In parallel experiments  -GalCer
effectively protected wild-type B6 mice against EAE (data not shown).
Representative data are shown from three separate experiments.
Figure 7. CNS antigen-specific responses in IL-4 KO and IL-10 KO
mice immunized with MOG35–55 peptides and treated with  -GalCer.
B6.IL-4 /  (A) and B6.IL-10 /  (B) mice were immunized with
MOG35–55 peptide to induce EAE and treated with  -GalCer or vehicle
as described in the legend to Fig. 2. At day 11 after immunization cells
from inguinal and axillary lymph nodes were cultured with the indicated
concentrations (in  g/ml) of MOG35–55 peptide (A) or MBP (B). After
60 h of culture, supernatants were collected and cytokine levels were
measured by ELISA. Data shown represent the mean values   SE of four
mice in each experimental group. Representative data are shown from
three separate experiments.1808 Ligand-activated NKT Cells Protect Mice against EAE
mice against EAE.  -GalCer activates V 14 NKT cells and
polarizes these cells for loss of IFN-  production. Alterna-
tively, the NKT cells from  -GalCer–injected mice may
lose the capacity to induce IFN-  production by other cell
types, such as NK cells. In turn, these altered early immune
responses influence adaptive immune responses against the
immunizing CNS antigens, thus effectively shifting the bal-
ance from a pathogenic Th1 toward an innocuous or pro-
tective Th2 response. Future studies will be aimed at test-
ing this hypothesis.
In addition to its protective effects on EAE,  -GalCer
protects non-obese diabetic (NOD) mice against Type 1
diabetes (64–66), and has some efficacy in experimental
models for inflammatory bowel disease (67). In the case of
Type 1 diabetes, the protective effects of  -GalCer corre-
lated with its ability to suppress IFN-  production by NKT
cells and to promote islet autoantigen-specific Th2 cell re-
sponses (64, 65). Thus,  -GalCer may prove useful for
treatment of a variety of diseases, including MS, Type 1
diabetes, and rheumatoid arthritis, that are mediated by
pathogenic Th1 cells and where a Th2 bias is beneficial.
With regard to the clinical applications of  -GalCer
therapy, it should be noted that  -GalCer induces signifi-
cant liver toxicity in mice (68). However, no adverse ef-
fects have been observed in clinical trials for using  -Gal-
Cer as a treatment for human cancers (69). In addition,
potential toxic effects of  -GalCer therapy may be over-
come with analogs of this chemical that are also recognized
by NKT cells (39, 54), or by combining  -GalCer therapy
with reagents such as IL-7 (70), IL-18 (71), anti-CD86 an-
tibodies (72), and anti-CD154 antibodies (73), that suppress
Th1 or enhance Th2 cytokine production by NKT cells.
In this context, combined  -GalCer and IL-7 therapy is
superior for prevention of autoimmune diabetes in NOD
mice (65) and anti-CD86 antibodies synergize with  -Gal-
Cer for treatment of EAE disease (72).
It was recently reported that an analogue of  -GalCer,
termed OCH, with a truncated sphingosine chain, prefer-
entially stimulates NKT cells to produce IL-4 (74). These
investigators further showed that a single injection of the
OCH analogue at the time of priming of B6 with MOG35–55
peptides provides partial protection against EAE (74).
However, using the same treatment protocol  -GalCer did
not alter EAE (72, 74). The latter finding is at variance
with the studies presented here and is most likely due to
differences in the administration protocol. Yamamura and
colleagues gave mice a single  -GalCer injection at the
time of priming, whereas our standard treatment protocol
involves three injections at days 0, 4, and 7 after EAE in-
duction. In fact, our treatment protocol using  -GalCer
provides more robust protection against EAE than the pro-
tocol of Yamamura and colleagues using OCH. Thus, ad-
ministration of OCH according to our treatment protocol
should provide more optimal protection against disease
than reported by Yamamura and colleagues (74) and de-
scribed here for  -GalCer.
One striking property of the CD1d antigen presentation
pathway is its remarkable conservation among different
species (42, 44, 45). Thus,  -GalCer binds both mouse and
human CD1d and is recognized by invariant NKT cells
from either species (39, 42, 44, 45). Therefore, the studies
presented here for mice are directly relevant to modulation
of human autoimmune diseases.
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